The 2020 Innovation to Commercialization and Health Professional-Investigator awardees are applying research and innovations to improve health outcomes for British Columbians.
By investing in and supporting health research, we are continuing to support British Columbians through the pandemic and our province’s economic recovery.
Dr. Brian Kwon and his research team are using MSFHR funding to advance a novel technology to improve outcomes for patients with spinal cord injury.
MSFHR and Mitacs have partnered to support joint applications so researchers can access both Mitacs and MSFHR funding with one application. MSFHR and Mitacs have partnered to support joint applications so researchers can access both Mitacs and MSFHR funding with one application.
Our 2020 Innovation to Commercialization (I2C) competition is now open. Read on for more details, including program competition changes for 2020.
Nine BC health researchers have been funded in MSFHR’s third Innovation to Commercialization (I2C) competition. Each will receive funding to advance their medical treatments, diagnostic tools and assistive technologies towards practical application to improve health outcomes and enrich the health innovation ecosystem in BC.
Applications are now open for the 2019 Innovation to Commercialization competition. The letter of intent deadline is March 14, with full applications due May 2, 2019.
2003 Scholar and 2017 I2C award recipient Dr. David Granville has identified an enzyme potentially responsible for skin blistering, and is developing an inhibitor to prevent and treat the condition.
Eight BC health researchers have been funded in MSFHR’s second Innovation to Commercialization competition, designed to help researchers advance discoveries or inventions towards practical application.
Christopher Ong, one of MSFHR’s first Innovation to Commercialization cohort, says his 2017 I2C award came at an opportune time in the development of a new drug that could stop prostate cancer in its tracks.